Publications
February 9, 2024
Neurology
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3
July 14, 2021
International Journal of Toxicology
Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease
May 11, 2021
Advances in Therapy
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
Posters
March 2024
2024 Muscular Dystrophy Association Clinical and Scientific Conference
Disease Burden in Patients with Spinal Muscular Atrophy (SMA) Treated with Survival Motor Neuron (SMN)-Targeted Therapies: A Targeted Literature Review
March 2024
2024 Muscular Dystrophy Association Clinical and Scientific Conference
Effect of apitegromab on motor function and patient-reported outcomes at 36 months in patients aged 2–21 years with spinal muscular atrophy
February 2024
Keystone Symposia: Obesity Causes and Consequences Conference
SRK-439, a Selective Anti-Pro and Latent Myostatin Antibody, Maintains Lean Mass and Enhances Fat Mass Lossin Models of Pharmacologically Induced Weight Loss